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FLT3-TKDBackground: Alterations of the FLT3 gene are the most frequent molecular aberrations seen at diagnosis of
acute myeloid leukemia (AML). Two main types of FLT3 mutations have been the most commonly
detected; internal tandem duplication (ITD) in the juxtamembrane domain and point mutation D835Y
in the tyrosine kinase domain (TKD). Both classes of mutations result in constitutive activation of FLT3
receptor/CD135.
Aim: To assess the frequency of FLT3 gene mutations (ITD and TKD D835Y) and the flow cytometric
expression of FLT3 receptor/CD135 among AML patients to define the role for FLT3 receptor expression
in predicting FLT3 gene mutational status and mRNA transcript level.
Subjects and methods: Eighty AML patients at diagnosis and 20 control subjects were enrolled. FLT3 recep-
tor/CD135 expression, FLT3 gene mutations, and FLT3 transcript level were evaluated by flow cytometry,
conventional polymerase chain reaction (PCR), and quantitative real-time reverse-transcription PCR,
respectively. Fluorescence in situ hybridization was done to stratify patients into favorable, intermediate,
and poor cytogenetic risk groups.
Results: FLT3-ITD was detected in 22.5% AML patients, while none had FLT3-TKD D835Y mutation. A cut-
off value of >17% was assigned to define FLT3 receptor/CD135+ cases. FLT3 receptor/CD135 and FLT3 tran-
scripts were overexpressed in 100% AML patients; higher levels were found among AML-M5 subtype and
poor cytogenetic group. AML patients harboring FLT3-ITD showed a trend for higher FLT3 receptor/CD135
expression and FLT3 transcript level than those with wild-type FLT3. FLT3 receptor/CD135 >49% was pre-
dictive for FLT3-ITD. A positive correlation was found between FLT3 receptor/CD135 expression and FLT3
transcript level.
Conclusion: Evaluation of FLT3 receptor/CD135 expression by flow cytometry at diagnosis of AML could
constitute a predictor for the FLT3-ITD mutational status and FLT3 transcript level.
 2018 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acute myeloid leukemia (AML) is a remarkably complex neo-
plasm with considerable genetic, epigenetic, and phenotypic
heterogeneity [1]. Gene expression profiling has improved the
molecular classification and prognosis of AML, where molecular
testing has become mandatory for AML with normal cytogenetics
to further classify into prognostic groups [2]. Among the genetic
aberrations, alterations of the FMS-like tyrosine kinase 3 (FLT3)
gene have been shown to play a substantial role in AML pathogen-
esis and prognosis [3].
The FLT3 gene maps to chromosome 13q12.2, consists of 24
exons, spans 96 kb, and encodes a tyrosine kinase receptor that
plays a key role in controlling survival, proliferation, and
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main types of activating mutations in the FLT3 gene have been
identified and represent the most frequently observed molecular
aberrations at diagnosis of AML; the internal tandem duplications
(ITDs) in exon 14 and 15 encoding the juxtamembrane domain
(JMD), generated by the in-frame insertion of 18 to more than
100 bp, and the missense point mutations in exon 20, most com-
monly involving the amino acid substitution aspartic acid to tyro-
sine in codon 835 (D835Y) of the activation loop of the tyrosine
kinase domain (TKD). These mutations lead to loss of the autoinhi-
bition exerted by the JMD over the TKD resulting in overexpression
or constitutive ligand-independent phosphorylation/activation of
the FLT3 receptor, disturbing the intracellular signaling networks
and deregulating the delicate balance between cell proliferation
and differentiation. Less commonly in AML, ITDs can occur in the
TKD, and point mutations in the JMD; although these mutations
lead to constitutive activation of the receptor, their biological
and clinical role remains to be clarified [5]. While there are diverg-
ing data concerning the prognostic impact for missense TKD muta-
tions, many studies have supported that ITDs represent a major
independent adverse prognostic indicator associated with
increased risk for relapse and worse overall survival in AML
patients [6–8].
FLT3 receptor/CD135, also known as FLK2 (fetal liver tyrosine
kinase 2) or STK1 (stem cell tyrosine kinase 1), is a transmembrane
tyrosine kinase receptor composed of 933 amino acids, with a
molecular weight of 155–160 kDa, belonging to class III family of
receptor tyrosine kinases. FLT3 receptor is composed of five extra-
cellular immunoglobulin-like domains, transmembrane domain
(TMD), JMD, and TKD consisting of two lobes (TK1 and TK2) inter-
connected by a tyrosine kinase insert [5]. FLT3 receptor is normally
expressed on the surface of hematopoietic stem/progenitor cells
and is lost upon hematopoietic cell differentiation [6]. The FLT3
ligand (FLT3L) is expressed both as a soluble form and a
membrane-bound form by cells of the bone marrow (BM) microen-
vironment, including BM stromal cells and hematopoietic progen-
itor cells [3]. FLT3/FLT3L interaction induces receptor dimerization
that promotes phosphorylation of tyrosine residues in the TKD andTable 1
Clinical and laboratory characteristics of AML patients.
Parameters AML patients (n = 80)




Hepatosplenomegaly, n (%) 24 (30)
Lymphadenopathy, n (%) 20 (25)
TLC (109/L), median (IQR) 29.9 (10.9–66.1)
Hemoglobin (g/dL), mean ± SD 7.9 ± 1.7
Platelets (109/L), median (IQR) 49 (21.5–102)
BM blasts (%), mean ± SD 79.6 ± 18.6











Not available 6 (7.5)
FLT3 mRNA expression level, median (IQR) 35 (19.5–83)
FLT3 receptor/CD135%, mean ± SD 53.2 ± 22.4
AML, acute myeloid leukemia; BM, bone marrow; FAB, French-American-British; FLT3, FM
n, number; SD, standard deviation; TLC, total leucocytic count; WT, wild-type; *, P-value
and P-value <0.01 is highly-significant.JMD, resulting in activation of the receptor and its downstream
effectors, stimulating survival and proliferation, and inhibiting
apoptosis of progenitor cells [5]. Overexpression of the FLT3 recep-
tor has been reported to be associated with high risk for relapse in
AML patients [9–11].
This study aimed to assess the frequency of FLT3 gene muta-
tions (ITD and TKD D835Y), and the flow cytometric expression
of FLT3 receptor/CD135 among a cohort of de novo AML patients
to define the role for FLT3 receptor expression in predicting FLT3
gene mutational status and mRNA transcript level.2. Subjects and Methods
This study was conducted on 80 newly-diagnosed de novo AML
patients admitted to the Hematology/Oncology Unit, Ain Shams
University Hospitals during the period March 2015 to January
2017. They were 46 males and 34 females (male to female ratio,
1.4:1), with mean age 43.7 ± 19.9 years (range, 23–65 years).
Twenty age- and sex-matched healthy individuals recruited from
BM donors candidate for allogenic BM transplantation were
enrolled as a control group. They were 12 males and 8 females
(male to female ratio, 1.5:1), with mean age 45.3 ± 16.7 years
(range, 21–55 years). Informed written consents were obtained
from patients and controls prior to enrollment. All procedures
were in accordance with the standards of the Ethical Committee
for Human Experimentation of Ain Shams University and the Hel-
sinki Declaration of 1964, as revised in 2008. The patients were
diagnosed and classified according to the World Health Organiza-
tion (WHO) proposed criteria of myeloid neoplasms and acute leu-
kemia [12]. The clinical and laboratory characteristics of AML
patients are summarized in Table 1.2.1. Sampling
Peripheral blood (PB) and BM specimens were collected on
potassium ethylene diamine tetra-acetic acid (K-EDTA) (1.5 mg/
mL) for morphologic, immunophenotypic, and molecular analyses,FLT3-ITD (n = 18) FLT3-WT (n = 62) P-value*
44.1 ± 20.6 43.5 ± 20.1 0.942
8 (44.4) 38 (61.3)
0.45610 (55.6) 24 (38.7)
6 (33.3) 18 (29) 1.000
4 (22.2) 16 (25.8) 1.000
31.8 (3.9–50) 28 (11–68.4) 0.373
7.9 ± 2.5 7.9 ± 1.5 0.944
48 (38–112) 50 (18–94) 0.560
76.2 ± 22.5 80.6 ± 17.5 0.542
4 (22.2) 8 (12.9)
0.413
2 (11.1) 8 (12.9)
6 (33.3) 20 (32.3)
6 (33.3) 10 (16.1)
0 (0) 14 (22.6)
0 (0) 2 (3.2)
8 (44.4) 20 (35.7)
0.184
10 (55.6) 20 (35.7)
0 (0) 16 (28.6)
0 (0) 6 (9.7)
47 (39–92) 30 (18–82) 0.060
64.2 ± 17.2 50 ± 23 0.070
S-like tyrosine kinase 3; IQR, interquartile range; ITD, internal tandem duplication;
for comparison between FLT3-ITD and FLT3-WT groups. P-value <0.05 is significant,
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(FISH).
2.2. Flow cytometric immunophenotyping for standard acute leukemia
panel and surface FLT3 receptor/CD135 expression
Immunophenotyping was performed on BM/PB specimens
using the standard panel of FITC/PE/PC5-labeled monoclonal anti-
bodies for acute leukemia (CD45, CD34, CD38, HLA-DR, CD117,
CD13, CD33, CD14, myeloperoxidase [MPO], CD19, CD10, CD20,
CD79a, CD22, terminal deoxynucleotidyl transferase [TdT], CD2,
CD3, CD5, CD7) (Beckman Coulter, Miami, USA) on Epics XL flow
cytometer (Beckman Coulter, Inc., Hialeah, FL, USA). Antigens were
scored positive using a cut-off value of 20% or more leukemic blasts
staining brighter than an isotype-matched negative control (anti-
mouse IgG1, Beckman Coulter). A cut-off value of 10% was used
for CD34, MPO, and TdT [13].
The FLT3 receptor/CD135-PE-labeled monoclonal antibody
(R&D Systems, Minneapolis, MN, USA) was used for evaluation of
the surface expression of FLT3 receptor/CD135. Fresh specimens
were counted using Coulter LH 750 Hematology Analyzer (Beck-
man Coulter Inc., Fullerton, California, USA), and the total leuco-
cytic count (TLC) was adjusted to 5.0  109/L using phosphate-
buffered saline (8.5 g NaCL, 1.07 g Na2HPO4, 0.39 g NaH2PO4, in 1
L deionized water, adjusted to pH 7.4; Sigma-Aldrich, Saint Louis,
MO, USA). Fifty lL of the adjusted specimens were added to the
control and test tubes, as well as 5 lL of the isotype-matched neg-
ative control and FLT3 receptor/CD135-PE monoclonal antibody
added to the control and test tubes, respectively. The control and
test tubes were incubated at room temperature, protected from
light, for 15 min, followed by the addition of 1–2 mL of ammonium
chloride-based erythrocyte lysing solution (8.29 g [0.15 M] NH4Cl,
1 g [10 mM] KHCO3, 0.037 g [0.1 mM] EDTA, in 1 L distilled water,
adjusted to pH 7.3; Sigma-Aldrich, Saint Louis, MO, USA). Tubes
were vortexed and analyzed on Coulter Epics XL flow cytometer.
FLT3 receptor/CD135 expression was assessed on the gated
CD45dim/side scatter (SSC) low blast cell region. The percentage
of FLT3 receptor/CD135+ blast cells was determined as a percent-
age of the gated blast cell population.
2.3. Conventional polymerase chain reaction (PCR) for FLT3 gene
mutations
The LeukoStratTM FLT3 Mutation Assay-Gel Detection (Invivo-
scribe Technologies, Inc., CA, USA) was used for PCR-based detec-
tion of FLT3 activating ITD and TKD mutations. FLT3-ITD master
mix contained dNTPs, the forward (5‘-CAATTTAGGTATGAAAGCC-
3‘) and reverse (50-GTACCTTTCAGCATTTTGAC-30) primers, whereas
FLT3-TKD D835Y master mix contained dNTPs, the forward
(50-CCGCCAGGAACGTGCTTG-30) and reverse (50-GCAGCCTCA
CATTGCCCC-30) primers (Invivoscribe Technologies, Inc., USA). Pos-
itive and negative control DNAs (Invivoscribe Technologies, Inc.,
USA), AmpliTaq Gold DNA polymerase (Applied Biosystems, Life
TechnologiesTM, USA), 100 bp DNA ladder (Invitrogen, Life Tech-
nologiesTM, USA), and EcoRV restriction endonuclease for TKD
mutation (Invitrogen, Life TechnologiesTM, USA) were used. The
DNA was extracted from fresh BM/PB specimens using QIAamp
DNA Mini kit (Qiagen, Germany) according to the manufacturer’s
protocol. The eluted DNA was buffered and stored at 30 C till
assay.
VeritiTM thermal cycler (Applied Biosystems, Life TechnologiesTM,
USA) was employed for DNA amplification with conditions of ini-
tial denaturation at 95 C for 7 min followed by 34 cycles of denat-
uration at 94 C for 30 s, annealing at 55 C for 30 s, and extension
at 72 C for 1 min, then a final extension step at 72 C for 10 min.
EcoRV restriction endonuclease digest was performed post PCRfor the FLT3-TKD D835Y master mix. Amplified PCR products
together with DNA molecular weight marker were run on 2% agar-
ose gel stained with ethidium bromide.
FLT3-ITD alleles yield a product that exceeds 330 bp, whereas
FLT3-wild-type alleles yield a 330 bp product. FLT3-TKD D835Y
mutant alleles yield a 130 bp digestion product, whereas FLT3-
wild-type alleles yield an 80 bp digestion product from the original
undigested amplicon product of 150 bp.
2.4. Real-time reverse-transcription polymerase chain reaction (qRT-
PCR) for quantification of FLT3 mRNA transcript level
qRT-PCR for the FLT3 mRNA transcript level was performed
using the QuantiFast Probe RT-PCR Plus kit designated for quanti-
tative, probe-based, real-time, one-step RT-PCR with integrated
genomic DNA removal (Applied Biosystems, Foster City, CA, USA).
QuantiFast Probe Assay for FLT3 target gene included forward
primer (50-TTTCACAGGACTTGGACAGAGATTT-30), reverse primer
(50-GAGTCCGGGTGTATCTGAACTTCT-30), and FAM-labeled TaqMan
probe (50-TCCAAATTCCAGCATGCCTGGTTCAAG- 30), whereas
QuantiFast Probe Assay for b-actin reference gene included forward
primer (50-TGACGGGGTCACCCACAC-30), reverse primer (50-CTAGA
AGCATTTGCGGTGGA-30), and VIC-labeled TaqMan probe (50-TTC
ACCACCACGGCCGAGC- 30). Both QuantiFast Probe Assays were
labeled with a non-fluorescent quencher. The total RNA was
extracted from fresh BM/PB specimens using QIAamp RNA Blood
Mini kit (Qiagen, Germany) according to the manufacturer’s
protocol. The eluted RNA was immediately flash frozen in liquid
nitrogen and stored at 70 C till assay.
The reaction protocol started with reverse transcription at 50 C
for 20 min, followed by 40 cycles of heating at 95 C for 5 min (hot
start PCR), heating at 95 C for 15 s (denaturation), and finally heat-
ing at 60 C for 30 s (annealing/extension). PCR and data analysis
were carried out on Applied Biosystems StepOneTM (Applied Biosys-
tems, Life TechnologiesTM, USA).
FLT3 expression levels in unknown specimens were calculated
by relative quantification using the DDCT method which relies
on comparison of cycle threshold (CT) values of FLT3 (target gene)
to b-actin (reference gene) in unknown and normal calibrator spec-
imens. The results were presented as the fold change in gene
expression normalized to the endogenous reference gene and rela-
tive to the normal calibrator [14].
2.5. Fluorescence in situ hybridization (FISH)
Probes for t(8;21)(q22;q22), t(15;17)(q22;q12), t(9;22)(q34;
q11), trisomy 8, and 11q23 rearrangement (Vysis, Downers Grove,
USA) were used. The patients were stratified into cytogenetic-
based risk groups: favorable; t(8;21)(q22;q22) and t(15;17)(q22;
q12), intermediate; normal karyotype and trisomy 8, and poor;
t(9;22)(q34;q11) and 11q23 rearrangement [12].
2.6. Statistical analysis
Statistical Program for Social Science, version 20 (SPSS Inc., Chi-
cago, IL, USA) was used for data analysis. Categorical data were
expressed in the form of frequency and percentage. Continuous
data were expressed in the form of mean ± standard deviation
(SD), or median and interquartile range (IQR) for parametric and
non-parametric variables, respectively. Fisher’s exact test was used
for comparison of categorical variables between two independent
groups. Student t-test and Mann-Whitney test were used for com-
paring continuous parametric and non-parametric variables
between two independent groups, respectively. ANOVA and
Kruskal-Wallis tests were used for comparing continuous paramet-
ric and non-parametric variables between more than two study
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were used to assess the strength of association between parametric
and non-parametric variables, respectively. The receiver operating
characteristic (ROC) curve was employed to assign the best cut-off
value for FLT3 receptor/CD135% positivity and predictability for
FLT3-ITD. P-value of <0.05 was considered significant and of
<0.01 was considered highly-significant in all analyses.
3. Results
3.1. FLT3 receptor/CD135 expression in AML patients
FLT3 receptor/CD135 expression was higher in AML patients
(mean ± SD, 53.2 ± 22.4%) compared with control subjects (mean
± SD, 8.4 ± 4.7%) (p < 0.001). Representative example for flow cyto-
metric expression of surface FLT3 receptor/CD135 in BM specimen
of control subject and AML patient is shown in Fig. 1. ROC curve
was constructed to determine the best cut-off value for FLT3 recep-
tor/CD135% positivity in AML patients; a cut-off of >17% was
assigned to define FLT3 receptor/CD135+ cases with 100% sensitiv-
ity, specificity, positive predictive value (PPV), negative predictive
value (NPV), and efficacy (area under curve = 1; p < 0.001). Accord-
ingly, 80 of 80 (100%) AML patients were FLT3 receptor/CD135+,
and 20 of 20 (100%) control subjects were FLT3 receptor/CD135-.
FLT3 receptor/CD135 expression was not equally distributed
among the different FAB subtypes, recording the highest expres-Fig. 1. Flow cytometric expression of surface FLT3 receptor/CD135 in bone marrow sp
negative CD135 expression (13%), Lower Panel; AML patient showing positive CD135 exsion in M5 followed by M3, M0, M2 and M1 (p = 0.001). Similarly,
FLT3 receptor/CD135 expression was higher in the poor cytoge-
netic risk group compared with the intermediate and favorable risk
groups (p = 0.007). In contrast, FLT3 receptor/CD135 expression
was consistent in relation to gender, hepatosplenomegaly, and
lymphadenopathy (p > 0.05) (Table 2).
FLT3 receptor/CD135 expression was positively correlated with
the percentage of BM blasts (r = 0.659; p = 0.023), while no signif-
icant correlations were found with age (r = 0.124), TLC (rs = 0.127),
hemoglobin (Hb) level (r = 0.021), and platelets count (rs = 0.113)
(p > 0.05).3.2. FLT3 gene mutations in AML patients
FLT3-ITD was detected in 18 of 80 (22.5%) AML patients, while
none of the patients had FLT3-TKD D835Y mutation. Control sub-
jects showed neither FLT3-ITD nor FLT3-TKD D835Y mutation.
Although AML patients harboring FLT3-ITD mutation had higher
FLT3 receptor/CD135 expression and FLT3 mRNA transcripts than
those with wild-type FLT3, the difference showed a trend with fail-
ure to reach statistical significance (p = 0.07; p = 0.06, respectively)
(Table 1, Fig. 2). FLT3-ITD mutational status was comparable in
relation to other clinical and laboratory characteristics of AML
patients (p > 0.05) (Table 1).ecimen of control subject and AML patient. Upper Panel; control subject showing
pression (86%). SS LOG, side scatter log.
Table 2







Male 49.7 ± 21.5
0.255
30 (18–82)
0.331Female 57.9 ± 23.3 42 (22–115)
Hepatosplenomegaly
Yes 63.3 ± 21.5
0.060
77 (30–92)
0.042*No 48.9 ± 21.7 29.5 (18–48.5)
Lymphadenopathy
Yes 60.1 ± 22.8
0.232
38.5 (27–92)
0.444No 50.7 ± 22.1 35 (19–82)
FAB subtypes




M1 42.6 ± 18.7 19 (14–50)
M2 43.1 ± 17.9 30 (18–43)
M3 60.6 ± 19.6 32.5 (28–103.5)
M5 77.6 ± 18.3 115 (72–147)
Cytogenetic risk groups
Favorable 49.5 ± 21.6
0.007**
29.5 (21–42)
0.023*Intermediate 46.3 ± 17.1 30 (18–47)
Poor 73.7 ± 21.9 83 (82–125)
AML, acute myeloid leukemia; FAB, French-American-British; FLT3, FMS-like tyrosine kinase 3; IQR, interquartile range; SD, standard deviation; *, P-value <0.05 is significant;
**, P-value <0.01 is highly-significant.
Fig. 2. FLT3 receptor/CD135 expression (A) and FLT3 mRNA transcript levels (B) in FLT3-ITD and FLT3-WT patient groups. WT, wild-type.
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FLT3 mRNA transcripts were detected in 80 of 80 (100%) AML
patients, with higher levels found in AML patients; median (IQR),
35 (19.5–83), compared with control subjects; median (IQR),
1 (0.7–1.4) (p < 0.001).
FLT3 mRNA transcript level was higher in AML patients pre-
sented with hepatosplenomegaly (p = 0.042). Moreover, FLT3
mRNA transcript level was not equally distributed among the dif-
ferent FAB subtypes, recording the highest expression in M5 fol-
lowed by M3, M2, M1 and M0 (p = 0.007). Similarly, FLT3 mRNA
transcript level was higher in the poor cytogenetic risk group com-
pared with the intermediate and favorable risk groups (p = 0.023).
In contrast, FLT3 mRNA transcript level was comparable in relation
to gender and lymphadenopathy (p > 0.05) (Table 2).
No significant correlations were found between FLT3 mRNA
transcript level and age (rs = 0.084), TLC (rs = 0.017), Hb level
(rs = 0.047), platelets count (rs = 0.092), and percentage of BM
blasts (rs = 0.188) (p > 0.05).3.4. Role for FLT3 receptor/CD135 expression in predicting FLT3-ITD
and FLT3 mRNA transcript level in AML patients
ROC curve was constructed to define the best cut-off value for
FLT3 receptor/CD135% that could predict the presence of FLT3-
ITD at diagnosis of AML. FLT3 receptor/CD135 >49% predicted
FLT3-ITD with 89% sensitivity, 61.3% specificity, 40% PPV, 95%
NPV, and 67.5% efficacy (area under curve = 0.708; p = 0.01). More-
over, a positive correlation was found between FLT3 receptor/
CD135% and FLT3 mRNA transcript level (rs = 0.965; p < 0.001)
(Fig. 3).4. Discussion
In this study, we detected FLT3-ITD in 18 of 80 (22.5%) AML
patients, while none of our patients showed FLT3-TKD D835Y
mutation. Control subjects showed neither FLT3-ITD nor FLT3-
TKD D835Y mutation. FLT3-ITD was first detected by Nakao and
Fig. 3. Positive correlation between FLT3 receptor/CD135% and FLT3 mRNA
transcript level in AML patients.
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followed by many study groups reporting the incidence of FLT3-ITD
to range from 10 to 38% [6,11,16–20]. Previous studies [6,11,21]
have also denoted the low incidence for FLT3-TKD D835Y mutation
in AML, ranging from 4 to 7%.
We assigned a cut-off value of >17% to define FLT3 receptor/
CD135+ AML patients. FLT3 receptor/CD135 and FLT3 mRNA were
overexpressed in all studied AML patients compared with controls.
Other studies have reported FLT3 receptor/CD135 overexpression
as well as increased median expression levels of FLT3 transcripts
in 70–100% AML patients [10,11].
In the present study, we found comparable differences between
each of FLT3 receptor/CD135, FLT3-ITD, and FLT3 mRNA, and the
patients’ age and gender, complying with the results of other stud-
ies [11,22,23]. We also did not find significant association between
each of FLT3 receptor/CD135 and FLT3-ITD and the clinical param-
eters of AML patients, however, FLT3 mRNA was significantly ele-
vated in AML patients presented with hepatosplenomegaly.
Moreover, no significant correlations were found between each
of FLT3 receptor/CD135, FLT3-ITD, and FLT3 mRNA, and the studied
hematological parameters except for a significant positive correla-
tion between FLT3 receptor/CD135 expression and percentage of
BM blasts.
Vora and coworkers [23] found no association between FLT3
receptor/CD135 expression and TLC or Hb level, yet found signifi-
cant association with the percentage of BM blasts; the latter could
be expected due to the impact of overexpressed FLT3 receptor on
the uncontrolled proliferation and survival of BM leukemic blast
cells. Abd El-Ghaffar et al. [24] and Kuchenbauer et al. [10] also
reported significant association of FLT3 receptor/CD135 with high
TLC and BM blast count.
Peng and colleagues [22] found FLT3-ITD was associated with
higher TLC and percentage of BM blasts, yet their acute leukemia
study group comprised a mixture of AML, B-acute lymphoblastic
leukemia (ALL), and T-ALL. Mehta et al. [7] reported a trend for
FLT3-ITD with low Hb level and low platelets count, while detected
similar incidence for FLT3-ITD among the TLC subgroups. They also
showed that FLT3 mRNA was not related to TLC, although they
could find significant associations between FLT3 mRNA and low
Hb level, low platelets count and high percentage of BM blasts;
they alternatively employed absolute quantification of FLT3 mRNA
transcript level and sub-grouped their patients considering the
median value as the cut-off level (<16  105 and 16  105). Fur-
thermore, Kuchenbauer et al. [10] reported significant associationof FLT3 mRNA with leucocyte and BM blast counts. This difference
could possibly be related to their inclusion of AML with
myelodysplasia-related changes and therapy-related AML among
their de novo AML patients as well as to the use of SYBR Green
instead of Taqman probes.
Interestingly, FLT3 has been reported to be persistently
expressed during the process of monocyte differentiation, where
the ligand for FLT3 is required for complete differentiation of
monocytes from CD34+ cells. Thus, it has been proposed that
FLT3 signaling is more likely to be associated with AML-M5 sub-
type [3,24,10]. In agreement, we found FLT3 receptor/CD135
expression and FLT3 mRNA transcript level to be highest among
AML-M5 patients, whereas none of our FLT3-ITD+ patients were
classified as AML-M5 or related to other FAB subtypes.
Although FLT3 mutations have long been identified within the
intermediate cytogenetic risk group of AML patients especially
those having normal karyotype [25], we found the highest FLT3
receptor/CD135 expression and FLT3 mRNA transcript level among
the poor cytogenetic risk group. This may be because the highest
level for both FLT3 receptor/CD135 expression and FLT3 mRNA
transcript was among AML-M5 patients with 11q23 (MLL) rear-
rangement which has been classified among the poor cytogenetic
risk group. In contrast, Abd El-Ghaffar et al. [24] found comparable
FLT3 receptor/CD135 expression among the cytogenetic risk
groups; a finding possibly confounded by the inclusion of pediatric
among adult AML patients, the former being known for its lower
frequency of FLT3-ITD than the latter [26].
In our study, although there was a trend for higher expression
of FLT3 receptor/CD135 and FLT3 mRNA transcripts among FLT3-
ITD than FLT3-wild-type AML patients, the results could not reach
statistical significance. Receiver operating characteristics showed
that FLT3 receptor/CD135 expression by >49% blast cells could pre-
dict FLT3-ITD+ AML patients. These findings complied with the
results reported by Peng and coworkers [22] who found that
despite the upregulated FLT3 receptor/CD135 and FLT3mRNA tran-
scripts in patients with FLT3-ITD, the difference was comparable.
Hence, it could be indicated that quantification of FLT3 receptor
and FLT3 transcripts detects the total expression of both wild-
type and mutant alleles [11]. However, according to Abd El-
Ghaffar et al. [24], higher levels of FLT3 receptor/CD135 were
found among CD135+FLT3-wild-type than CD135+FLT3-ITD
patients, and a cut-off level of <62% for CD135 was determined
to indicate FLT3-ITD mutation. Moreover, Riccioni et al. [3]
reported that 10–15% AML patients display high expression of
FLT3 receptor associated with wild-type FLT3 which represents
an unfavorable prognosis, the same as that with FLT3-ITD.
An explanation for the association of FLT3 receptor/CD135 over-
expression with wild-type FLT3 rather than FLT3-ITD was provided
by Kuchenbauer et al. [10] who hypothesized that high FLT3 mRNA
expression may represent an alternative to the mutational activa-
tion of the FLT3 receptor. In the same context, they denoted that
FLT3 transcriptional upregulation is associated with a partial loss
of the wild-type allele, whereas a total loss of the wild-type frag-
ment (ITD/-) leads to low FLT3 expression, proposing that FLT3
expression in the presence of FLT3-ITD depends on the coexpres-
sion of wild-type and mutant alleles.
As the quantity of total cellular protein expression essentially
reflects the gene transcript level, in congruence with others
[10,22] we found a significant positive correlation between FLT3
receptor/CD135 expression and FLT3 mRNA transcript level.
The identification of FLT3 receptor expression levels and its
molecular mutations represent new opportunities in the treatment
of AML. Over the past decades, the biology and function of wild-
type and mutant FLT3 receptor have been well characterized [5].
Different compounds including tyrosine kinase inhibitors and
immunotherapy using anti-FLT3 monoclonal antibody have been
M.A. Mekawy et al. / The Egyptian Journal of Medical Human Genetics 19 (2018) 345–351 351investigated in vitro and in vivo as FLT3 inhibitors; however, clini-
cal trials have produced only partial and transitory results. There-
fore, additional data about FLT3 receptor expression levels and
molecular mutations are still required to investigate the underly-
ing causes for resistance to FLT3 inhibitors in a trial to optimize
AML treatment protocols [5,27].
5. Conclusions
Our study provides further insights and contributes to under-
standing the role for FLT3 receptor expression in predicting FLT3-
ITD mutational status and FLT3 gene expression. We propose that
evaluation of FLT3 receptor/CD135 expression by flow cytometry
in association with the standard acute leukemia panel at diagnosis
of AML could constitute a predictor for FLT3-ITD mutational status
and FLT3 mRNA transcript level. The frequent overexpression of
FLT3 receptor in AML, with or without FLT3-ITD, points to its
importance in selecting patients who could likely benefit from
the incorporation of FLT3 inhibitors along with conventional
chemotherapy. The identification of FLT3-ITD using more advanced
methodologies as the next generation sequencing or capillary
electrophoresis-based fragment analysis, considered as the gold
standard for FLT3-ITD detection since conventional electrophoresis
of amplified FLT3 sequences may not be sensitive enough for small
ITD insertions, are warranted. Future studies to evaluate the poten-
tial role for FLT3 receptor expression level in predicating the ITD
allelic burden and length are worthwhile.
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